目的探讨化疗联合恩度治疗晚期非小细胞肺癌的临床疗效和不良反应发生情况。方法选取2010年1月~2012年12月本院接收的100例晚期非小细胞肺癌患者为研究对象,平均分成两组,实验组与对照组,各50例。对照组患者单独给予化疗,实验组患者实施化疗联合恩度治疗,比较两组患者的临床疗效和不良反应。结果实验组患者完全缓解18例(36%),部分缓解24例(48%),总有效率为84%,明显高于对照组总有效率62%,两组比较差异具有统计学意义(P<0.05);实验组患者白细胞和血小板减少的发生率较对照组有明显降低,两组比较差异具有统计学意义(P<0.05)。结论化疗联合恩度治疗晚期非小细胞肺癌可显著提高临床疗效,有效控制癌症的发展和恶化,且不良反应发生率较低,安全性好,是治疗晚期非小细胞肺癌的一种安全、有效的方法 ,值得在临床上推广。 Objective To investigate the clinical efficacy and adverse reactions of chemotherapy combined with Endometriosis in the treatment of advanced non-small cell lung cancer. Methods From January 2010 to December 2012, 100 patients with advanced non-small cell lung cancer received in our hospital were divided into two groups, the experimental group and the control group, with 50 cases each. The patients in the control group were given chemotherapy alone. The patients in the experimental group were treated with chemotherapy combined with Endue treatment, and the clinical efficacy and adverse reactions were compared between the two groups. Results In the experimental group, 18 cases (36%) were completely relieved, 24 cases (48%) partially relieved, the total effective rate was 84%, which was significantly higher than that of the control group (62%). There was significant difference between the two groups <0.05). The incidences of leukopenia and thrombocytopenia in the experimental group were significantly lower than those in the control group, with significant difference between the two groups (P <0.05). Conclusions Chemotherapy combined with Endue treatment of advanced non-small cell lung cancer can significantly improve clinical efficacy, effectively control the development and deterioration of cancer, and the incidence of adverse reactions is low, good safety, is a safe and effective treatment of advanced non-small cell lung cancer The method, it is worth in the clinical promotion.